secwatch / observer

8-K filed July 15, 2024, 7:59 PM ET ticker BNTC CIK 0001808898

other material confidence high sentiment positive materiality 0.75

Benitec reports durable swallowing improvements at 180 days for first BB-301 subject in Phase 1b/2a

Benitec Biopharma Inc.

Post-dose Total Pharyngeal Residue meaningfully reduced at 180 days vs pre-dose average for Subject 1.
For 3 of 4 food types, TPR at 180 days lower than any point in 9-month natural history study; fourth similar to lowest.
SSQ Total Score at 180 days lower than any point in 9-month pre-dose period, indicating improved swallowing.
No SAEs observed; transient Grade 2 GERD previously reported.
Second subject dosed Feb 2024; third expected Q3 2024; additional interim data in Q1 2025.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-24-179108
form_type: 8-K
ticker: BNTC
cik: 0001808898
company_name: Benitec Biopharma Inc.
filed_at: 2024-07-15T23:59:59+00:00
discovered_at: 2026-05-14T18:03:14.600764+00:00
generated_at: 2026-05-31T20:47:35.036020+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-24-179108
json_url: https://secwatch.observer/filing/0001193125-24-179108.json
markdown_url: https://secwatch.observer/filing/0001193125-24-179108.md
text_url: https://secwatch.observer/filing/0001193125-24-179108.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312524179108/0001193125-24-179108-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1808898/000119312524179108/d819205d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

TRTX

TRTX posts 1Q26 distributable earnings $0.25/sh, book value $11.06, loan portfolio $4.3B

TPG RE Finance Trust, Inc. June 1, 2026, 5:23 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AIB

Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline

BlockchAIn Digital Infrastructure, Inc. June 1, 2026, 4:57 PM ET other_material Items 1.01, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AII

American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit

American Integrity Insurance Group, Inc. June 1, 2026, 4:31 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Mid-America Apartments, L.P.

MAA May 2026 blended rents highest in 2 years; repurchased $50M shares

Mid-America Apartments, L.P. June 1, 2026, 4:20 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Liberty Global names Stephen van Rooyen as Ziggo Group CEO; plans Amsterdam listing in 2027

Liberty Global Ltd. June 1, 2026, 4:07 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-24-179108

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.